The Food and Drug Administration today announced it is requesting manufacturers immediately withdraw all prescription and over-the-counter ranitidine drugs (commonly known by the brand name Zantac) from the market.

This is the latest step in an ongoing investigation of the carcinogenic contaminant N-Nitrosodimethylamine (NDMA), which in some ranitidine products increases over time and when stored at higher than room temperatures to unacceptable levels.

The FDA advised consumers taking OTC ranitidine to stop taking any tablets or liquid they currently have, dispose of them properly and not buy more; patients taking prescription ranitidine should speak with their health care professional about other treatment options before stopping the medicine.

Related News Articles

Headline
WellSpan Health in York, Pa., will receive the 2024 AHA Quest for Quality Prize for its commitment to improving quality through its health equity strategic…
Headline
Access to quality mental and physical health services can be a complex challenge, but for individuals of color and people with severe or chronic mental…
Blog
ESPAÑOLWhat if one conversation can change, or even save, a life? That was the question AdventHealth sought to answer, as the health system launched a…
Perspective
Patient safety is the top priority of every caregiver. Hospitals and health systems never stop searching for ways to improve quality, performance and results…
Blog
The greatest success story of the 20th century is longevity. This is especially true in the United States, where average life expectancy at birth rose by more…
Headline
The AHA the week of July 8 released its Quality Collective Report, which explores quality, safety and performance improvement strategies and insights from…